C4 Therapeutics Inc · Q4 2021 earnings

Briefing

Reported full year financial results and business highlights for 2021.

C4 Therapeutics reported its full year 2021 financial results, highlighting progress across its organization, including dosing the first patient with its lead program and advancing additional candidates towards the clinic. The company's cash, cash equivalents, and marketable securities are expected to provide runway to the end of 2024.

• Clinical data from Cohort A of the ongoing Phase 1/2 trial of CFT7455 was accepted for presentation at the AACR Annual Meeting.
• Pre-clinical data on CFT7455, CFT8634, and CFT1946 was accepted for presentation at the AACR Annual Meeting.
• The CFT8634 Phase 1/2 clinical trial is expected to initiate in 1H 2022, and the CFT1946 IND application submission and Phase 1 trial initiation are expected in 2H 2022.
• Year-end cash, cash equivalents, and marketable securities are expected to provide runway to the end of 2024.

Headline financials

Revenue & EPS history

C4 Therapeutics expects that its cash, cash equivalents and marketable securities as of December 31, 2021, together with future payments expected to be received under existing collaboration agreements, will be sufficient to fund planned operating expenses and capital expenditures to the end of 2024.